The Effects of Cyproheptadine on Severe COVID-19 From the I-SPY COVID Adaptive Platform Trial

Sara C Auld1, Fady A Youssef1, Timothy E Albertson1

  • 1Division of Pulmonary, Allergy, Critical Care and Sleep Medicine (S. C. A.), Department of Medicine, Emory University, Atlanta, GA; the Pulmonary Division (F. A. Y.), Department of Internal Medicine, Long Beach Memorial Medical Centre, Long Beach; the Division of Pulmonary, Critical Care and Sleep Medicine (T. A.), Department of Medicine, University of California, Davis, Sacramento; the Division of Pulmonary Diseases and Critical Care Medicine (R. A. L.), Department of Medicine, University of California, Irvine, Irvine; the Hoag Memorial Hospital Presbyterian Center for Research and Education (P. R.), Newport Beach; the Department of Pulmonary and Critical Care Medicine (K. K. W.), Kaiser Permanente Los Angeles Medical Center, Los Angeles; the Division of Pulmonary, Critical Care, Allergy and Sleep Medicine (C. S. C. and M. A. M.), Department of Medicine, the Divisions of Nephrology and Critical Care Medicine (K. D. L.), Department of Medicine, the Department of Surgery (L. J. E.), University of California, San Francisco, San Francisco, CA; the Centre for Acute Respiratory Failure (J. R. B.), Columbia University, New York; the Department of Pulmonary and Critical Care Medicine (C. Q.), University of Rochester, Rochester, NY; the Department of Critical Care (P. A. B.), Sanford Health, Sioux Falls, SD; the Department of Medicine (E. L. B.), University of Colorado, Denver, CO; the Department of Pulmonary and Critical Care (N. C.), Georgetown University Medical Centre, Washington, DC; the Department of Medicine (E. F.), Main Line Health, Wynnewood; the Department of Medicine (N. J. M.), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; the Department of Pulmonary, Allergy, and Critical Care Medicine (S. G. and D. W. R.), University of Alabama at Birmingham, Birmingham, AL; the Department of Pulmonary Critical Care, Allergy and Immunologic Disease (K. W. G.), the Department of Internal Medicine (D. C. F.), Wake Forest University, Winston-Salem, NC; the Department of Cardiovascular and Thoracic Surgery (J. H.), Heart and Vascular Institute, West Virginia University, Morgantown, WV; the Division of Pulmonary and Critical Care Medicine (R. H.), Department of Medicine, University of Michigan, Ann Arbor; the Department of Pulmonary and Critical Care (M. M. H. S. K.), Spectrum Health, Grand Rapids, MI; the Section of Pulmonary, Critical Care, and Sleep Medicine (J. L. K.), Department of Medicine, Yale University, New Haven, CT; the Department of Critical Care Medicine (T. O.), Logan Health Research Institute, Kalispell, MT; the Department of Critical Care Medicine (S. S.), Mercy Hospital, Springfield, MO; the Pulmonary and Critical Care Division (R. G. W.), Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL; and the Department of Medical Epidemiology and Biostatistics (M. E.), Karolinska Institutet, Stockholm, Sweden.

CHEST Critical Care
|September 26, 2026
PubMed
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...